Hormonal receptor status and tumour cell proliferation have been evaluated as potential predictive factors for chemotherapy (Corle et al, 1984; Willsher et al, 1998; Zambetti et al, 1999), but these tumour properties have so far shown little clinical utility. This evidence concerns the gene NR4A1 and neoplasm.